Both AstraZeneca/Bristol Diabetes Drugs Should Meet FDA Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca execs maintain during earnings call that clinical trial programs for dapagliflozin and saxagliptin satisfy new regulatory requirements.
You may also be interested in...
New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes
Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting
New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes
Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting
Dapagliflozin Performance In Phase III Leaves Concerns,Particularly About Urinary Infections
Phase III results for Bristol-Myers Squibb/AstraZeneca’s dapagliflozin released at the 2010 American Diabetes Association meeting are raising questions about whether the SGLT-2 inhibitor and others like it have a chance at competing for a second-line role against DPP-4 inhibitors, despite worrisome urinary infection side effects.